SUSTAINED RELEASE SOLID DOSAGE FORMS HAVING NON-UNIFORM DISTRIBUTION OF ACTIVE INGREDIENT

Abstract: This invention relates to sustained-release, solid-dosage forms having non-uniform distribution of active ingredient which provides for zero-order release of the active ingre­ dient. The non-uniform distribution is accomplished by providing for a multitude of enveloping, concentric layers over a central core. Each of the various layers having constant concentration of a hydrophilic gel and each layer and the core having an amount of medicament defined by the expression D L = D T × R / R. wherein D L is the amount of medicament in the core or in any given sustained-release layer, D T is the total amount of medicament in the sustained-release portion of the tablet, R D is the differential radius for the core or the enveloping layer for which the amount of required medicament is to be determined and R T is the radius of the sustained-release portion of the tablet.

Description: SUSTAINED RELEASE SOLID DOSAGE FORMS RAVING NON-UNIFOSM PISTRIBUTION OF ACTIVE INGREDIENT The desirability of sustained-action pharmaceutical forms has long been recognized as desirable in terms of patient convenience and optimum availability of drug. Sustained-action dosage forms provide rapid availability and maintenance of medicament at a level sufficient to provide a desired biological effect. The sustainedaction dosage forms are to be distinguished from prolonged-action dosage forms which provide an initial amount of medicament which may exceed the upper limit of the desirable therapeutic range and which subsequently will provide medicament within the desirable therapeutic range for a longer time than will a conventional dosage form. Currently available, so called sustained-action dosage forms operate as prolongedaction dosages and merely mimic the desired sustainedrelease effect. L. Lachman, B.A. Lieberman and J.L. Kanig, The Theory and Practice of Industrial Pharmacy, Lea and Febiger, 1970, page 409. Traditionally, pharmaceutical dosage forms contain an active component distributed uniformly throughout. For sustained-release solid dosage forms where release of drug is primarily by diffusion or erosion, uniform concentration leads to a non-linear, i.e., non zero order, release profile. In an eroding system, the surface area exposed to dissolution diminishes with time, thereby causing a reduction in drug-release rate. In systems where diffusion is the primary release mechanism, the rate of release is dependent on the gradient of drug concentration between the dosage form and dissolution environment. Depletion of drug from the system causes a reduction in this gradient which slows release rate. Applicant has discovered that non-uniform concentration can be used as a means of countering diffusion or erosion effects. Applicant's novel dosage forms provide for zeroorder release of active ingredient and are suitable for use in sustained release formulations. The desired release of medicament is accomplished by preparing a solid dosage form having a core and one or more concentric enveloping layers or press coats wherein the concentration of medicament is greatest in the core and diminishes in each subsequent outer layer. A solid dosage form having such a distribution of medicament avoids the non-linear release of prior art solid dosage forms having uniform distribution -of active ingredients. As applicant's dosage forms erode, reducing available surface area, the greater drug concentration in the core negates the diminishment of drug-release rate. Where applicant's dosage forms release drug primarily by diffusion, non-uniform distribution eliminates the reduction of gradient inherent in diffusing dosage forms having uniform drug distribution. SUMMARY OF THE INVENTION Applicant has discovered that solid dosage forms, having a core and one or more concentric enveloping sustained-release layers or press coats, wherein the concentration of medicament is greatest in the core and diminishes in each subsequent outer layer, provide for a substantially zero-order release of active ingredient. The amount of medicament in the core or in any given layer is determined by the formula EMI3.1 wherein DL is the amount of medicament in the core or in any given layer, DT is the total amount of medicament in the tablet, RD is the differential radius for the core or the enveloping layer for which the amount of required medicament is to be determined and RT is the radius of the tablet. DETAILED DESCRIPTION OF TBE INVENTION Solid dosage forms, as used herein, include pressed or compressed tablets, molded tablets, pills and extruded suppositories. Compressed tablets are preferred because of ease in manufacturing and consumer acceptance. Applicant's solid-dosage forms have a central core and one or more concentric enveloping sustained-release layers or press coats. Ideally, there would be an infinite number of sustained-release layers of infinitesimally small thickness. For practical reasons, primarily due to the limitation of presently available tableting machinery, ten (10) or so layers over the core would be the uppermost limit. For example, the Manesty Bicot p manufactured by Manesty Machines Limited, can produce a triple pressed tablet from three separate granulations and a fourth coat can be pressed on by using a device to recycle the triple pressed tablet. Applicant's preferred solid-dosage form is a tablet having a core and from 1 to 4 enveloping layers. More preferably, the dosage form would have a core and one enveloping layer. Applicant also contemplates that one or more outer layers may be used to effect a variety of purposes other than sustained release. For example, tablets may be coated to protect the ingredients from the atmosphere, to mask unpleasant-taste, to improve appearance, to control the site of action of the drug such as an enteric coating, and to provide a rapidly dissolving outer layer to provide for quick onset of action followed by zero order sustained release. These optional layers may be accomplished by sugar coating, film coating, compression coating and any other method known to the art. In a preferred embodiment, an outer, quic'xly-dissolving , non-sustained release layer would contain medicament needed for rapid onset- of action and several inner, sustained-release layers and core would contain additional amounts of the medicament or would optionally contain a second medicament whose sustainedrelease action would compliment the effect of the medicament in the outer, non-sustained release layer. For example, a preferred tablet of applicant's invention has a core and 3 enveloping layers wherein the quickly- dissolving, outermost layer contains terfenadine, an antihistamine, and wherein the sustained-release core and inner layers contain pseudoephedrine hydrochloride, a bronchodilator. Tfie core and the enveloping layers may be any thickness but solid dosage forms in excess of 25.4 .mm thick are quite undesirable from the consumer's point of view. Although it is highly desirable to have a multitude of very thin layers, practicle limitations render this goal quite difficult to attain. For example, current tableting technology precludes press-coated layers less than about 0.8 mm thick. Extruded solid dosage forms cannot have layers less than about 1 mm thick. Applicant prefers 1 to 4 press coated layers over a central core, wherein the layers are about 2.4 mm thick. Applicant's novel dosage forms rely on the ability of hydrophilic gels to swell in contact with water and retard the release of medicament. As used herein, a hydrophilic gel is any substance which gels when in contact with water, and swells slowly from the outer surface to the core resulting in diffusion or erosion of the drug from the swollen matrix. Substances having these properties are well known to those skilled in the pharmaceutical arts. Examples of suitable hydrophilic gels for use in the present invention are hydroxypropyl methylcellulose (EPIC), hydroxypropyl cellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropyl ethylcellulose, methylcellulose, carboxyethylcellulose, carboxymethyl hydroxyethylcellulose, methylcellulose cross-linked with dialdehyde, Carbopol&commat;, polyvinyl alcohol cross-linked with glyoxal, formaldehyde or glutaraldehyde, poly(N-vinyl-2-pyrrolidone), poly(hydroxyalkyl methacrylate), esters of 2-hydroxyethyl methacrylate, acrylates such as AquakeepsX, N-vinyl lactams, poly acrylic acids such as Goodrite&commat; ;, poly acrylamides such as Cyanamer3, maleic anhydride plus styrene co-polymer, maleic anhydride plus ethylene propylene, butylene or isobutylene co-polymer, crosslinked polyethylene oxides, polyethylene oxide, indene anhydride polymer, starch graft polymers, poly glucan cross-linked diesters, cross-linked poly acrylamides, and natural gums such as carraghenin, alginate gum, guar gum and carob gum. Moreover, applicant contemplates the use of mixtures of hydrophilic gels to effect particular release rates. however, the same hydrophilic gel or mixture of hydrophilic gels must be utilized in the core and sustained-release enveloping layers in order that applicant's mathematical expression be useful in determining the appropriate quantity of medicament. It is, of course, possible that by judicious choice of different hydrophilic gels and their mixtures in the core and enveloping layers, a tablet could be prepared providing substantially zero order release of medicament. however, applicant's mathematical expression would not predict the amounts of medicament to be used in the core and layers. Applicant prefers HPMC, particularly HPMC having a viscosity of 4000 mpa.s , as a hydrophlic gel for use in the present invention. Applicant also prefers a mixture of hydrophilic gels containing 1 part of HPMC having a viscosity of 4000 rnPa.s and 3 parts of EPNC having a viscosity of 100 mPa.s. Applicant's tablets can contain one or more exclpients in addition to the medicament and hydrophilic gel. With the exception of tablet disintegrants, which tend to break apart the tablet, any other pharmaceutical excipient may be used. Suitable tablet excipients for use in applicant's tablets are, for example, diluents such as lactose, dextrose, mannitol, sorbitol, gelatin, acacia, dicalcium phosphate, tricalcium phosphate or monocalcium phosphate; binders such as sucrose, polyethylene glycol, polyvinylpyrrolidone; lubricants such as stearic acid, zinc, calcium or magnesium stearate, or talc, colorants such as FD & dyes/and the likes, and flavoring agents. In practicing the present invention, it is apparent that the amount of medicament in"the core or a sustained release layer is determined by applicant's formula and the amount of hydrophilic gel is determined by the desired release rate. The amount of pharmaceutical excipients varies as necessary to provide the total weight required for the core or layer. The total weight required is a quantity readily determined by those with ordinary skill in the art and depends on the volume of the core or layer and *the compressibility of the materials. In the preferred tablet formulations of this invention, applicant prefers that the diluents, mannitol and lactose, be used to complete the total weight required of the core and layers. Applicant further prefers that the lubricant, zinc stearate, be used in all compressed tablet formulations. Medicaments which are suitable for use in the solid dosage forms of this invention include any drug substance or combination of drug substances which can be formulated in a solid dosage form and for which sustained release administration would be desirable. Suitable drug substances and their indications are acetaminophen, an antipyretic; aminophylline, a smooth muscle relaxant; amitriptyline HC1, an antidepressant; betamethasone phosphate, a glucocorticoid; brompheniramine maleate, an antihistaminic; buphenine BC1, a peripheral vasodilator; carbetapentane citrate, an antitussive; carbocromene EC1, a coronary vasodilator; chlorpheniramine maleate, an antihistaminic; chlorpromazine ECl, a tranquilizer; clonidine ECl; an antihypertensive; codeine phosphate, an antitussive; diethylpropion SC1, an anorexiant; dihydroergotamine mesylate, a cerebral vasodilator; dextromethorphan "Br, an antitussive; diphylline, a bronchodilator; ergotamine tartrate, a vasoconstrictor; fenfluramine HC1, an anorexiant; ferritin, an antianemic; furosemide, a diuretic antihypertensive; heptaminol HC1, a cardiotonic; hydroquinidine ECI, an antiarrhythmic; ibuprofen, an anti-inflammatory; imipramine HCl, an antidepressant; indomethacin, an anti-inflammatory; isoxsuprine HCl, a vasodilator; isosorbide dinitrate, a coronary vasodilator; metformin HC1, a hypoglycemic agent; melperone, a neuroleptic; methscopalamine bromide, an antispasmodic; noscopine HCl, an antitussive; oxeladin citrate, an antitussive; papaverine HC1, a smooth muscle relaxant and cerebral vasodilator; pentazocine lICl, an analgesic; phenylephrine HC1, a sympathomimetic vasoconstrictor; phenylpropanolamine HC1, a sympathomimetic bronchodilator; potassium chloride, a potassium source for the treatment of hypokalemia; procainamide ECl, an antiarrhythmic; propranolol BC1, a beta receptor blocker, antihypertussive and antiarrhythmic agent; pseudoephedrine HC1; a bronchodilator and peripheral-vasocon- strictor; theophylline, a smooth muscle relaxant, bronchodilator and myocardial stimulant; terbutaline sulfate, a bronchodilator; terfenadine, an antihistamine; and trihexyphenidyl HC1, an anti-Parkinsonian agent. Terbutaline, pseudoephedrine Etc1, terfenadine, melperone and 4-ethyl-l, 3-dihydro-5- (4-pyridinylcarbonyl )- 2H-imidazol-2-one are preferred drug substances. Although any drug substance can be administered by sustained release, for various reasons, certain drug substances when administered via sustained release formulations, offer little or no advantage over more conventional modes of administration. For example, sustained release administration is contraindicated or is of questionable value for a) drugs with long biological half lives (i.e., greater than 10 hours) such as chlorpromazine and thioridazine; b) drugs absorbed by active transport, as for example, quaternary ammonium compounds such as propantheline bromide; c) antibotics such as penicillins and cephalosporins; d) drugs destroyed by first pass liver metabolism and/or metabolism in the gut wall such as ritodrine, salicylamide or lidocaine; and drugs that are naturally sustained release, for example, medicaments which are absorbed in body fat and subsequently are slowly released into the patients blood, such as chlorpromazine and thioridazine. Any amount of medicament can be formulated into the solid dosage forms of the present invention. Due to the limitations on the size of the dosage form and the large amount of medicament necessary in the core, dosage forms of this invention should not exceed about 500 mg of medicament. Applicant prefers dosage forms having 300 mg or less of medicament. Dosage forms of this invention having greater than 300 mg of medicament will require departure from cylindrical shapes to oval or capsule shaped forms in order to accommodate the high concentration of medicament in the core of the dosage form. In principle, there is no lower limit on the amount of medicament which can be formulated into the dosage forms of this invention. However, applicant prefers dosage forms having at least 0.1 mg of medicament. The rate of medicament release from applicant's tablets, whether by tablet erosion or by diffusion, is determined by medicant concentration as well as the hydrophilic gel and its concentration. Other factors, such as compression force in pressed tablets, appear to have little, if any, effect. The relationship between release rate and medicament concentration is linear, that is, as the medicament concentration is doubled, for example, the release rate is likewise doubled. Reducing the hydrophilic gel concentration in a given dosage form, increases the release rate of the medicament in a semi-logarithimic manner. That is, b reducing the concentration of a given hydrophilic gel by half in an otherwise identical dosage form, the release rate of the medicament would increase by a factor of approximately 1.25. Thus, it is apparent that by judicious choice of medicament concentration, hydrophilic gel concentration and the choice of hydrophilic gel, a wide range of release rates can readily be obtained. The sustained dosage forms of applicant'stinven- tion are intended to effect substantially zero order release of medicament from 1 hour to 2 days, preferably from 4 to 24 hours, more preferably from 8 to 12 hours depending on medicament concentration as well as the hydrophilic gel and its concentration. In order to assure zero order release of medicament, the concentration of hydrophilic gel in the core and sustainedrelease, enveloping layers must be essentially a constant. The solid dosage forms of this invention can be of any shape, however, in using applicant's mathematical expression, it will be necessary to orient, at least conceptually, the shape of the dosage form to correspond to a cylinder and designate lines thru the center of the dosage form corresponding to the cylindrical axis of height and radial axis. For example, in the typical biconvex circular tablet, the axis of height extends from the center of one convex surface to the other through the center of the tablet. The radial axis extends outward from the axis of height at the tablets center to the circular edge. In solid dosage forms having a capsule shape, the axis of height and radial axis are readily apparent by analogy to a cylindrical solid. In determining the amount of medicament to be used in the core or any layer, it is necessary to chose-a radial axis along which the differential radius of the core or a layer is measured. Where the shape of the solid dosage form is such that the axis corresponding to the radial axis of a cylinder is not readily apparent, some trial and error may be necessary. To determine the amount of medicament to be used in the core or in any layer, the applicant has derived a mathematical expression based on certain theoretical considerations. Although the derivation of thts expres- sion was based on solid dosage forms having the shape of a cylindrical solid and solid dosage forms which release medicament by erosion, the resulting expression has been found to be useful in dosage forms of a variety of shapes and dosage forms which release medication by diffusion as well as erosion. As used herein, the differential radius of a given dosage form is the thickness of the core or a given layer measured along the radial axis. Thus for the core, the differential radius is the distance from the center of the tablet to the outer edge of the core measured along the radial axis. The differential radius of a given layer is the distance from the inner edge to the outer edge of a given layer measured along the radial axis. Where the tablet shape is such that the measurement along the radial axis will vary depending on the direction of the axis, an average value for differential radius should be used. For example, in tablets which are prismoidal solids, the length of the radial axis will vary depending on whether the axis extends outward toward a corner of the tablet edge, toward a face of the tablet edge or toward a point in between. To determine the amount of medicament to be used in the core or an enveloping layer of-the solid dosage forms of applicant's invention, the following mathematical expression has been derived: EMI12.1 wherein DL is the amount of medicament in the core or in any given layer, DT is the total amount of medicament in the sustained-release portion of the tablet; RD is the differential radius for the core or the enveloping layer for which the amount of required medicament is to be determined and RT is the radius of the sustainedrelease portion of the tablet. Although the above expression has general application to solid dosage forms which release medicament by erosion and diffusion, applicant has derived a second expression for dosage forms which release medicament exclusively, or nearly so, by diffusion. The diffusion equation is: EMI12.2 wherein DL, DT and RT are as in the erosion expression above and wherein RSD is the squared differential radius. The squared differential radius for a given sustained release layer or the core is the difference between the square of the distance from the outer surface of the sustained-release portion of the tablet to the inner edge of the layer to be determined (the center of the tablet for the core) and the square of the distance from the outer surface of the sustainedrelease portion of the tablet to the outer edge of the layer to be determined (zero for the outermost layer) measured along the radial axis of the tablet. - Average values should be used for irregularly shaped dosage forms. Although the latter expression theoretically thus thus constitutes a aSrefenBd embodiment of this invention works better for diffusing dosage forms/, the applicant nevertheless prefers the former erosion expression for use in calculating doses for all solid dosage forms of this invention. A tablet of this invention wherein the distribution of medicament in the core and sustained release layers is determined by means of the above-mentioned mathematical expression, will release medication in a substantially zero-order fashion. That is, the amount of medicament released from a tablet of applicant's invention per unit of time will remain essentially constant until all medicament is released. While the release is normally substantially constant, in some instances there may be an initial release of medicament in a first order fashion, that is, initially more medicament will be released per unit of time than will be released during a subsequent unit of time which more closely imitates the desired zero-order release. The excess amount of medication released is said to be "dumped". This dumping effect occurs prior to and during the time period in which the tablet's hydrophilic gel layers are swelling to form a barrier to retard further release of medicament. Normally, this dumping period will not exceed a few hours, generally it does not exceed about 1 hour. Where it is desirable to reduce or eliminate this dumping effect, it will be necessary to deviate from the medicament distribution pattern predicted by applicant's mathematical expression. Because the dumped medication originates from the outermost sustained release layer, the typically, substantially zero-order release of medicament achieved by applicant's tablets can approximate constant release even more closely and any initial dumping of medicament reduced to negligible amdunts, by transferring some of the medication from the outermost sustained release layer to the inner layers or core. Preverably, this is accomplished by transferring an amount of medicament from the outermost sustained release layer to the penultimate sustained release layer or in the case of a tablet having only 1 sustained release layer, transferring some of the medicament from the sustained release layer to the core, The amount of medicament to be transferred from the outermost sustained release layer in order to reduce the dumping effect is approximately equal to the amount of medicament "dumped". Because all of the medicament dumped is assumed to come from the outermost sustained release layer in the first hour, the amount of medicament dumped is approximately equal to the difference between the amount of medicament released in the first hour and the amount released in any subsequent hour. The following examples illustrate the use of the above-mentioned mathematical expression in preparing various solid dosage forms. EXAMPLE 1 Sample Calculation for Cylindrical Dosage Form Raving Two Enveloping Layers Active ingredient 50 mg Differential Radii Core 6.35 mm (1/4 inch) Middle layer 6.35 mm (1/4 inch) Outer layer 12.70 mm (1/2 inch) Therefore, h = 25.40 mn (1 inch) Using the erosion expression for the core: EMI15.1 for the middle layer: EMI15.2 for the outer layer: EMI15.3 EXAMPLE 2 Sample Calculation for Capsule Shaped Tablet Havinq Two Enveloping Layers The tablet has a core wherein the axis of length is 14.3 mm : long and the radial axis measures 2.8 mm. The middle layer has an axis of length equal to 16.7 mm and the distance from the tablets center to the outer edge of the layer measured along the radial axis is 4 mm. * The outer layer has an axis of length equal to 19 mm : and the distance from the tablets center to the outer edge measured along the radial axis is 5.2 mm. The total amount of medicament is equal to 500 mg. The total radius measured along the radial axis is 5.2 mm. Using the erosion expression for the core: the differential radius is equal to the length of the core's radial axis, 2.8 mm. EMI15.4 for the middle layer: the differential radius is the difference between the length of the radial axis of the middle layer and the radial axis of the core, 1.2 mm EMI16.1 for the outer layer: the differential radius is the difference between the length of the radial axes of the outer and inner layers, 1.2 mm. EMI16.2 EXAMPLE 3 Sustained Release Tablet of l-(4-Fluorophen',rl)-4-(4- methyl-l-pil?eridinyl )-l-butanone Hydrochloride Having Two Enveloping Layers Tablet Specifications Total active. ingredient 50 mg Hydrophilic gel 18% HPNC 4000 mPa.s Lubricant 1.5% zinc stearate Filler mnnnitol (to weight required) Differential Radii Core 6.35 mm (1/4 inch) Middle layer 2.38 mm (3/32 incb) Outer layer 2.38 mm (3/32 inch) Therefore, using the erosion expression: Distribution of Active Ingredient Core 28.6 mg Middle layer 10.7 mg Outer layer 10.7 mg Therefore, suitable formulations are: : Core Middle Outer Layer Layer (ms) (mg) (ms) 1- (4-Fluorophenyl ) -4- (4-methyl-l-piperidinyll-butanone hydrochloride 28.6 10.7 10.7 Mannitol 51.9 134.2 190.55 HPMC 4000 mPa.s 18.0 32.4 45.0 Zinc stearate 1.5 2.7 3.75 Total Weight Requirement 100 mg 180 mg 250 mg EXAMPLE 4 Capsule Shaped Tablet of Melperone Having Two Enveloping Layers Tablet Specifications Active Melperone 50 mg Hydrophilic gel RPMC 4000 inPa.s 18%/layer Lubricant zinc stearate 1.5%/layer Filler lactose (to weight required) Differential Radii Core 2.41 mm (0.095 inch) Middle layer 0.64 mm (0.025 inch) - Outer layer 0.95 mm (0.0375 inch) Total Radius 4.00 mm (0.1575 inch) Therefore the granulations required are: Core Middle Outer Layer Layer (mg) (mg) (ms) Melperone 30 8 * 12 EPNC 12 22 52 Zinc stearate 1 1.8 4.4 Lactose 25 88.2 221.6 Total weight Requirement 65 mg 120 mg 290 mg EXAMPLE 5 Nelperone Extruded Suppository Having Two Enveloping Layers Specifications Active Melperone 50 mg/dosage form Hydrophilic gel HPMC D-50 40%/layer Excipients Glycerin 10% of gel weight Water to weight required Differential Radii Core 3 mm Middle layer 3 mm Outer layer 3 mm Therefore, the required Melperone is as follows: Core 16.67 mg Middle layer 16.67 mg Outer layer 16.67 mg Therefore, the required formulations are as follows: : Core Middle Outer Layer Layer (mg) (mg) Imq) Melperone 16.67 16.67 16.67 HPMC E-50 60.0 296.0 444.0 Glycerin 6.0 29.6 44.4 Water 67.33 397.73 604.93 Total Weight Requirement 150 mg 740 mg 1110 mg EXAMPLE 6 Terbutaline Sulfate Buccal Tablet Formulation Tablet Specification Terbutaline Sulfate 2 mg/tablet Hydrophilic gel BPMC 4000 mPa.s 18%/layer Lubricant zinc stearate 1.5%/layer Filler mannitol (to weight required) Differential Radii Core 1.6 mm (1/16 inch) Middle layer 0.8 mm (1/32 inch) Outer layer 0.8 mm (1/32 inch) Therefore, the required formulations are: : Core Middle Outer Layer Layer (ms) (mg) Terbutaline sulfate 1.0 0.5 0.5 HPMC 4000 mPa.s 2.7 5.4 ,9.9 Zinc stearate 0.225 0.45 0.825 Mannitol 11.075 23.65 43.775 Total Weight Requirement 15.0 mg 30.0 mg 55.0 mg EXAMPLE 7 Sample Calculation for Tablet with Two Enveloping Layers Using the Diffusion Expression Tablet Specifications Active ingredient 50 mg Total Radius 25.40 mm (1 inch) Differential Radii Core 6.35 mm (1/4 inch) Middle layer 6,35 mm (1/4 inch) Outer layer 12.70 mm (1/2 inch) Squared Differential Radii For the core: measured along the radial axis, the distance from the outer surface to the tablet center is 25.40 mm 4 1 inch) and the distance from the outer surface to the outer edge at the core is 19 mm (3/4 inch). Therefore, RSD = (25.40) - (19) = 284.16 mm (in inches: RSD = (l)2(3/4)2 = 7/16 inch Similarly, for the middle layer: RSD = (19) 2-12.70)2 = 199.71 (in inches: RSD = (3/4)2(1/2)2 = 5/16 for the outer = (12.70)20 = layer: RsD (12.70)2-0 = 161,29 (in inches: RSD = (l/2)20 = 1/4 Therefore, the distribution of active ingredient is calculated as follows: for the core: (in inches: EMI21.1 for the inner layer: EMI21.2 (in inches: EMI21.3 for the outer layer: EMI21.4 (in inches: EMI21.5

Claims: CLAIMS 1. A pharmaceutical tablet providing substantially zero-order release of medicament having a core and one or more enveloping sustained-release layers, the core and sustained-release enveloping layers consisting essentially of a mixture containing medicament, hydrophilic gel and excipients, wherein the concentration of hydrophilic gel in the core and in each sustainedrelease enveloping layer is essentially a constant and wherein the amount of medicament in either the core or in any given sustained-release layer is determined by the formula EMI22.1 wherein DL is the amount of medicament in the core or in any given sustained-release layer, DT is the total amount of medicament in the sustained-release portion of the tablet, RD is the differential radius for the core or the enveloping layer for which the amount of required medicament is to be determined and RT is the radius of the sustained-release portion of the tablet. 2. A tablet of-claim 1 having 1 enveloping layer. 3. A tablet of claim 2 wherein the hydrophilic gel is hydroxypropyl methylcellulose. 4. A tablet of claim 3 wherein the viscosity of the hydroxypropyl methylcellulose is 4000 mPa.s. 5. A tablet of claim 2 wherein the medicament is terbutaline. 6. A tablet of claim 2 wherein the medicament is terfenadine. 7. A tablet of claim 2 wherein the medicament is pseudoephedrine hydrochloride. 8. A tablet of claim 2 having an outer enveloping non-sustained, release layer. 9. A tablet of claim 8 wherein the medicament in the outer non-sustained, release layer is terfenadine and the medicament in the enveloping, sustained-release layer and core is pseudoephedrine hydrochloride. 10. A tablet of claim 1 having from 2 to 4 enveloping layers. 11. A tablet of Claim 10 wherein the hydrophilic gel is hydroxypropyl methylcellulose. 12. A tablet of claim 11 wherein the viscosity of the hydroxypropyl methylcellulose is 4000 mPa.s. 13. A tablet of claim 10 wherein the medicament is terbutaline. 14. A tablet of claim 10 wherein the medicament is terfenadine. 15. A tablet of claim 10 wherein the medicament is pseudoephedrine hydrochloride. 16. A tablet of claim 1 having 2 enveloping, sustained-release layers. 17. A tablet of claim 16 having an outer enveloping non-sustained, release layer. 18. A tablet of claim 17 wherein the medicament in the outer non-sustained, release layer is terfenadine and the medicament in the enveloping, sustained-release layers and core is pseudoephedrine hydrochloride.

Inventors: ZOGLIO, MICHAEL A.
Applicants: MERRELL DOW PHARMACEUTICALS INC.
Application year: 1983
Main classification: A61K9
IPC codes: A61K9